{"schema_version":"1.0","type":"article","title":"Revenue Jumped 39%, Yet Iovance Still Lost $47 Million: Can Cancer Cell Therapy Become a Business?","url":"https://drugnews.com.tw/articles/2026-08-17-iovance-amtagvi-til-commercialization-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-17-iovance-amtagvi-til-commercialization-en.md","lang":"en","date":"2026-08-17","publish_at":"2026-08-17T08:00:00+08:00","updated_at":"2026-08-17","category":"商業分析系列","topic":"商業分析系列","tags":["Iovance","Amtagvi","TIL","cancer cell therapy","melanoma","cell therapy","Timing Pharma"],"summary":"Iovance's Amtagvi rebounded sharply in the second quarter, but the central question is no longer whether TIL therapy can work. It is whether a personalized cell therapy can become a reproducible, reimbursable and scalable medical service.","key_points":[],"facts":[],"sections":["01 | This rebound is about a process that is beginning to work","02 | TIL is not a bag of drug. It is a relay that cannot break","03 | The overlooked cost is inside the hospital","04 | Ninety million dollars is not the finish line. It is the entry ticket","05 | Taiwan should focus on the whole chain from factory to bedside","References","Disclaimer"],"references":[{"title":"[Iovance 2026 Q2 results press release]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465926091619/tm2622322d1_ex99-1.htm"},{"title":"[Iovance 2026 Q2 Form 10-Q]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465926091716/iova-20260630x10q.htm"},{"title":"[Iovance 2026 Q1 results press release]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465926056782/tm2613648d1_ex99-1.htm"},{"title":"[FDA Amtagvi product page]","source":"","date":"","url":"https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/amtagvi"},{"title":"[FDA approval announcement for Amtagvi]","source":"","date":"","url":"https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-to-treat-patients-with-unresectable-or-metastatic-melanoma"},{"title":"[Amtagvi prescribing information]","source":"","date":"","url":"https://www.fda.gov/media/176417/download"},{"title":"[FDA Summary Basis for Regulatory Action]","source":"","date":"","url":"https://www.fda.gov/media/176951/download"},{"title":"[ClinicalTrials.gov NCT05727904]","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT05727904"},{"title":"[ClinicalTrials.gov NCT02360579]","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT02360579"},{"title":"[TPEx emerging stock disclosure for Timing Pharma]","source":"","date":"","url":"https://wwwov.tpex.org.tw/storage/eb_data/11412/11400105781.html"},{"title":"[Timing Pharma cell therapy services]","source":"","date":"","url":"https://www.timing-pharmacy.com/service"},{"title":"Verification cutoff: August 18, 2026.","source":"","date":"","url":""}],"images":[{"alt":"Figure 1 | Iovance's Q2 rebound shows that TIL commercialization is starting to move, but profitability is not yet proven","url":"https://drugnews.com.tw/assets/articles/iovance-amtagvi-til-commercialization-en/figure-01.png"},{"alt":"Figure 2 | TIL therapy is a relay from referral and tumor harvest to manufacturing, hospitalization, infusion and reimbursement","url":"https://drugnews.com.tw/assets/articles/iovance-amtagvi-til-commercialization-en/figure-02.png"},{"alt":"Figure 3 | The hospital is part of the product: TIL commercialization depends on ICU readiness, payer approval and standardized execution","url":"https://drugnews.com.tw/assets/articles/iovance-amtagvi-til-commercialization-en/figure-03.png"},{"alt":"Figure 4 | The next decade will depend on conversion rate, manufacturing scale, hospital execution, reimbursement and confirmatory data","url":"https://drugnews.com.tw/assets/articles/iovance-amtagvi-til-commercialization-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/iovance-amtagvi-til-commercialization-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-17）。Revenue Jumped 39%, Yet Iovance Still Lost $47 Million: Can Cancer Cell Therapy Become a Business?。https://drugnews.com.tw/articles/2026-08-17-iovance-amtagvi-til-commercialization-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh":"2026-08-17-iovance-amtagvi-til-commercialization.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}